Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 3

Status

Recruiting 13Active not recruiting 8Completed 7Terminated 5Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Gynecologic 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Non Hematologic Cancers 1Neoplasms 1Lung Neoplasms 1

Interventions

Cyclophosphamide 1488Cisplatin 1410Paclitaxel 1316Radiotherapy 1259Carboplatin 1247Gemcitabine 1214Docetaxel 1110Bevacizumab 1029Fluorouracil 894Doxorubicin 786Dexamethasone 746Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 673Etoposide 673Irinotecan 634Filgrastim 621Cytarabine 584Leucovorin 578Nivolumab 557Vincristine 510Prednisone 474Cetuximab 464Bortezomib 457Erlotinib Hydrochloride 456Trastuzumab 448Methotrexate 437Lenalidomide 426Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × Interventional × defactinib × Clear all
NCT03727880 2026-02-04

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

NCT04620330 2024-01-12

RAMP202

Verastem, Inc.

Phase 2 Completed
90 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02546531 2021-07-20

Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer

Washington University School of Medicine

Phase 1 Completed
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01778803 2017-05-17

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Verastem, Inc.

Phase 1 Completed
22 enrolled
Gynecologic

Ovarian Neoplasms

NCT01951690 2017-04-13

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Verastem, Inc.

Phase 2 Completed
55 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01943292 2017-03-09

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Verastem, Inc.

Phase 1 Completed
9 enrolled 7 charts

Non Hematologic Cancers

NCT00787033 2017-01-25

B0761001

Verastem, Inc.

Phase 1 Completed
46 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡